These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 27460076)

  • 1. The inflammatory microenvironment in epithelial ovarian cancer: a role for TLR4 and MyD88 and related proteins.
    Li Z; Block MS; Vierkant RA; Fogarty ZC; Winham SJ; Visscher DW; Kalli KR; Wang C; Goode EL
    Tumour Biol; 2016 Oct; 37(10):13279-13286. PubMed ID: 27460076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression and significance of the TLR4/MyD88 signaling pathway in ovarian epithelial cancers.
    Kim KH; Jo MS; Suh DS; Yoon MS; Shin DH; Lee JH; Choi KU
    World J Surg Oncol; 2012 Sep; 10():193. PubMed ID: 22985132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
    Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
    Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atractylenolide-I sensitizes human ovarian cancer cells to paclitaxel by blocking activation of TLR4/MyD88-dependent pathway.
    Huang JM; Zhang GN; Shi Y; Zha X; Zhu Y; Wang MM; Lin Q; Wang W; Lu HY; Ma SQ; Cheng J; Deng BF
    Sci Rep; 2014 Jan; 4():3840. PubMed ID: 24452475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer.
    d'Adhemar CJ; Spillane CD; Gallagher MF; Bates M; Costello KM; Barry-O'Crowley J; Haley K; Kernan N; Murphy C; Smyth PC; O'Byrne K; Pennington S; Cooke AA; Ffrench B; Martin CM; O'Donnell D; Hennessy B; Stordal B; Finn S; McCann A; Gleeson N; D'Arcy T; Flood B; O'Neill LA; Sheils O; O'Toole S; O'Leary JJ
    PLoS One; 2014; 9(6):e100816. PubMed ID: 24977712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
    Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
    Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atractylenolide I modulates ovarian cancer cell-mediated immunosuppression by blocking MD-2/TLR4 complex-mediated MyD88/NF-κB signaling in vitro.
    Liu H; Zhang G; Huang J; Ma S; Mi K; Cheng J; Zhu Y; Zha X; Huang W
    J Transl Med; 2016 Apr; 14(1):104. PubMed ID: 27118139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MyD88 and TLR4 Expression in Epithelial Ovarian Cancer.
    Block MS; Vierkant RA; Rambau PF; Winham SJ; Wagner P; Traficante N; Tołoczko A; Tiezzi DG; Taran FA; Sinn P; Sieh W; Sharma R; Rothstein JH; Ramón Y Cajal T; Paz-Ares L; Oszurek O; Orsulic S; Ness RB; Nelson G; Modugno F; Menkiszak J; McGuire V; McCauley BM; Mack M; Lubiński J; Longacre TA; Li Z; Lester J; Kennedy CJ; Kalli KR; Jung AY; Johnatty SE; Jimenez-Linan M; Jensen A; Intermaggio MP; Hung J; Herpel E; Hernandez BY; Hartkopf AD; Harnett PR; Ghatage P; García-Bueno JM; Gao B; Fereday S; Eilber U; Edwards RP; de Sousa CB; de Andrade JM; Chudecka-Głaz A; Chenevix-Trench G; Cazorla A; Brucker SY; ; Alsop J; Whittemore AS; Steed H; Staebler A; Moysich KB; Menon U; Koziak JM; Kommoss S; Kjaer SK; Kelemen LE; Karlan BY; Huntsman DG; Høgdall E; Gronwald J; Goodman MT; Gilks B; García MJ; Fasching PA; de Fazio A; Deen S; Chang-Claude J; Candido Dos Reis FJ; Campbell IG; Brenton JD; Bowtell DD; Benítez J; Pharoah PDP; Köbel M; Ramus SJ; Goode EL
    Mayo Clin Proc; 2018 Mar; 93(3):307-320. PubMed ID: 29502561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melatonin attenuates the TLR4-mediated inflammatory response through MyD88- and TRIF-dependent signaling pathways in an in vivo model of ovarian cancer.
    Chuffa LG; Fioruci-Fontanelli BA; Mendes LO; Ferreira Seiva FR; Martinez M; Fávaro WJ; Domeniconi RF; Pinheiro PF; Delazari Dos Santos L; Martinez FE
    BMC Cancer; 2015 Feb; 15():34. PubMed ID: 25655081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of BMI-1 dampens migration and EMT of colorectal cancer in inflammatory microenvironment through TLR4/MD-2/MyD88-mediated NF-κB signaling.
    Ye K; Chen QW; Sun YF; Lin JA; Xu JH
    J Cell Biochem; 2018 Feb; 119(2):1922-1930. PubMed ID: 28815730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of MyD88 expression by human epithelial ovarian carcinoma cells.
    Zhu Y; Huang JM; Zhang GN; Zha X; Deng BF
    J Transl Med; 2012 Apr; 10():77. PubMed ID: 22533866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TLR2 enhances ovarian cancer stem cell self-renewal and promotes tumor repair and recurrence.
    Chefetz I; Alvero AB; Holmberg JC; Lebowitz N; Craveiro V; Yang-Hartwich Y; Yin G; Squillace L; Gurrea Soteras M; Aldo P; Mor G
    Cell Cycle; 2013 Feb; 12(3):511-21. PubMed ID: 23324344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression and cellular distribution of TLR4, MyD88, and NF-κB in diabetic renal tubulointerstitial fibrosis, in vitro and in vivo.
    Liu P; Li F; Qiu M; He L
    Diabetes Res Clin Pract; 2014 Aug; 105(2):206-16. PubMed ID: 24894085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upregulation of Abelson interactor protein 1 predicts tumor progression and poor outcome in epithelial ovarian cancer.
    Zhang J; Tang L; Chen Y; Duan Z; Xiao L; Li W; Liu X; Shen L
    Hum Pathol; 2015 Sep; 46(9):1331-40. PubMed ID: 26193797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer.
    Szajnik M; Szczepanski MJ; Czystowska M; Elishaev E; Mandapathil M; Nowak-Markwitz E; Spaczynski M; Whiteside TL
    Oncogene; 2009 Dec; 28(49):4353-63. PubMed ID: 19826413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between the HMGB1/TLR4 signaling pathway and the clinicopathological features of ovarian cancer.
    Jiang C; Qu X; Ke H; Gong W; Chen R; Yang W; Cheng Z
    Mol Med Rep; 2018 Sep; 18(3):3093-3098. PubMed ID: 30015957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P-MAPA immunotherapy potentiates the effect of cisplatin on serous ovarian carcinoma through targeting TLR4 signaling.
    de Almeida Chuffa LG; de Moura Ferreira G; Lupi LA; da Silva Nunes I; Fávaro WJ
    J Ovarian Res; 2018 Jan; 11(1):8. PubMed ID: 29343281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical impact of high mobility group box 1 protein in epithelial ovarian cancer.
    Paek J; Lee M; Nam EJ; Kim SW; Kim YT
    Arch Gynecol Obstet; 2016 Mar; 293(3):645-50. PubMed ID: 26305032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the TLR4/Myd88/NF-κB Signaling Pathway on NLRP3 Inflammasome in Coronary Microembolization-Induced Myocardial Injury.
    Su Q; Li L; Sun Y; Yang H; Ye Z; Zhao J
    Cell Physiol Biochem; 2018; 47(4):1497-1508. PubMed ID: 29940584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.